IGF-1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-10 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
== History == Athletes in ancient Greece were advised to consume large quantities of meat and wine. A number of herbal concoctions and tonics have been used by strong men and athletes since ancient times across cultures to try to increase their strength and stamina. In the 1910s, Eugen Sandow, widely considered to be the first modern bodybuilder in the West, advocated the use of dietary control to enhance muscle growth. Later, bodybuilder Earle Liederman advocated the use of "beef juice" or "beef extract" (basically, consommé) as a way to enhance muscle recovery. In the 1950s, with recreational and competitive bodybuilding becoming increasingly popular, Irvin P. Johnson began to popularize and market egg-based protein powders marketed specifically at bodybuilders and physical athletes. The 1970s and 1980s marked a dramatic increase in the growth of the bodybuilding supplement industry, fueled by the widespread use of modern marketing techniques and a marked increase in recreational bodybuilding. In October 1994, the Dietary Supplement Health and Education Act (DSHEA) was signed into law in the USA. Under DSHEA, responsibility for determining the safety of the dietary supplements changed from the government to the manufacturer, and supplements no longer required approval from the U.S. Food and Drug Administration (FDA) before distributing the products. Since that time, manufacturers did not have to provide FDA with the evidence to substantiate safety or effectiveness unless a new dietary ingredient was added.
== Plot == Following a news story depicting the demolition of a slum in East London in the south-east of the Cape Province in South Africa, liberal white South African journalist Donald Woods seeks more information about the incident and ventures off to meet the anti-Apartheid black activist Steve Biko, a leading member of the Black Consciousness Movement. Biko has been officially banned by the National Party-led government and is not permitted to leave his defined 'banning area' at King William's Town. Woods is opposed to Biko's banning, but remains critical of his political views. Biko invites Woods to visit a black township to see the impoverished conditions and to witness the effect of the Government-imposed restrictions, which make up the apartheid system. Woods begins to agree with Biko's desire for a South Africa where blacks have the same opportunities and freedoms as those enjoyed by the white population. As Woods comes to understand Biko's point of view, a friendship slowly develops between them. After speaking at a gathering of black South Africans outside of his banishment zone, Biko is arrested and interrogated by the South African security forces (who have been tipped off by an informer). Following this, he is brought to court in order to explain his message directed toward the South African Government, which is white minority-controlled. After he speaks eloquently in court and advocates non-violence, the security officers who interrogated him visit his church and vandalise the property.
Big dynorphin acts as a potent full agonist at the human κ-opioid receptor (KOR), exhibiting extremely high relative efficacy at this target. In one binding assay it demonstrated similar affinity to dynorphin A, but about 14 to 32-fold higher potency to activate G proteins than other dynorphin peptides. In contrast, other studies have suggested similar or higher potencies of other dynorphins. The peptide is also an agonist of other opioid receptors, It is 70-fold selective towards KOR over μ-opioid receptors (MOR) and 200 over δ-opioid receptor (DOR). In older guinea-pig ileum bioassay measuring native receptor function, big dynorphin shows approximately 10-20-fold reduced potency relative to dynorphin A, possibly due to conformational constraints of the larger peptide affecting receptor binding in peripheral tissue. This discrepancy suggests that big dynorphin's efficacy in human KOR systems may not translate directly to potency in peripheral tissue. Big dynorphin could theoretically produce some of the classical pharmacological effects associated with KOR agonism such as dysphoria, dissociation, and sedation, but this has not been directly evaluated. Similarly biased signaling of big dynorphin at KOR has not yet been assessed.
Although Sonic has operated since the early 1950s, Sonic Corp. incorporated in Delaware in 1990. It has its corporate headquarters in Oklahoma City; the headquarters building features a dine-in Sonic restaurant in an adjacent building. Prior to its acquisition by Inspire Brands, its stock traded on NASDAQ with the symbol SONC. Most restaurants are owned and operated by franchisees. Total system sales as disclosed in 2026 were $5.2 billion.
Sources: en.wikipedia.org
ABS-201 is an AI-designed monoclonal antibody against the prolactin receptor (PRLR) currently in Phase 1/2a clinical trial for the treatment of androgenic alopecia (pattern hair loss) and endometriosis. It is taken by subcutaneous injection. ABS-201 is a possible first-in-class drug with a novel mechanism of action in the potential treatment of hair loss. ABS-201 is under development by Absci. It is believed that ABS-201 works by activating dormant hair follicles and causing them to move from the telogen phase to the anagen phase. In human ex vivo scalp model studies, ABS-201 stimulated hair regrowth, prolonged anagen phase, blocked catagen phase, inhibited telogen effluvium, and blocked hair from losing color. ABS-201 has been found to produce robust hair regrowth as compared with minoxidil in mice and balding macaques. The clinical trial for ABS-201 is being overseen by prominent hair loss researcher Rodney Sinclair, one of the principal investigators in minoxidil clinical trials. The chemical structure of the drug does not yet appear to have been disclosed.
=== Sampling calorimeters for detectors in high-energy particle physics === Depleted uranium has been used in a number of sampling calorimeters (such as in the D0 and ZEUS detectors) because of its high density and natural radioactivity.
Since its initial proposal, an expanding body of observational evidence—independent of the hypothesis itself—has reinforced the role of intracrine signaling in various physiological and pathological processes, including immune regulation, metabolic control, and cancer progression.
== Applications and detection methods == FFF is applicable in the sub-micron range (from 1 nm to several microns) in the "normal" mode or up to 50 microns in the so-called steric mode. The transition from normal to steric mode takes place when diffusion becomes negligible at sizes above a micron. FFF is unique in its wide dynamic range of sizes covering both soluble macromolecules and particles or colloids which can be separated in one analysis. Typical applications are high molar mass polymers and polymer composites, nanoparticles, both industrial and environmental, viruses and virus like particles, lipid nanoparticles, extracellular vesicles and other types of biological samples. FFF can be coupled to all types of detectors known, from high-performance liquid chromatography (HPLC) to size-exclusion chromatography (SEC). Due to FFF's similarity to liquid chromatography (LC), a liquid mobile phase passing through the channel, the most common detectors are those that are also used for liquid chromatography. The most frequently used is an ultraviolet-visible spectroscopy (UV-VIS) detector, because of its non-destructive nature. Coupling with multi angle light scattering which allows the calculation of the size of eluting fractions and comparison to values obtained via FFF theory. Another popular detector is inductively coupled plasma mass spectrometry to characterize metallic nanoparticles with high specificity and sensitivity.
=== Hormonal control === Lactiferous duct development occurs in females in response to circulating hormones. First development is frequently seen during pre- and postnatal stages, and later during puberty. Estrogen promotes branching differentiation, whereas in males testosterone inhibits it. A mature duct tree reaching the limit of the fat pad of the mammary gland comes into being by bifurcation of duct terminal end buds (TEB), secondary branches sprouting from primary ducts and proper duct lumen formation. These processes are tightly modulated by components of mammary epithelial ECM interacting with systemic hormones and local secreting factors. However, for each mechanism the epithelial cells' "niche" can be delicately unique with different membrane receptor profiles and basement membrane thickness from specific branching area to area, so as to regulate cell growth or differentiation sub-locally. Important players include beta-1 integrin, epidermal growth factor receptor (EGFR), laminin-1/5, collagen-IV, matrix metalloproteinase (MMPs), heparan sulfate proteoglycans, and others. Elevated circulating level of growth hormone and estrogen get to multipotent cap cells on TEB tips through a thin, leaky layer of basement membrane. These hormones promote specific gene expression. Hence cap cells can differentiate into myoepithelial and luminal (duct) epithelial cells, and the increased amount of activated MMPs can degrade surrounding ECM helping duct buds to reach further in the fat pads.
Sources: en.wikipedia.org
== Causes == The etiology, or causes, of BPD involves several causes, with no consensus on a single one. BPD may share a connection with post-traumatic stress disorder (PTSD), with both having a traumatic substrate. While childhood trauma is a recognized contributing factor, the roles of congenital brain abnormalities, genetics, neurobiology, and non-traumatic environmental factors remain subjects of ongoing investigation.
The defense along the Vistula took place from August 1944 until the renewed Soviet offensive in January 1945. By January 1945, the 4th Panzer Army was holding static defensive positions on Hitler's direct orders and during the lull in the fighting it had created a defensive zone in southern Poland. On 1 January 1945, the 4th Panzer Army, then under Army Group A, had a total strength of 133,474 men spread across seven infantry divisions (68th, 72nd, 88th, 168th, 291st, 304th, 342nd), two Panzergrenadier divisions (10th, 20th), two panzer divisions (16th, 17th), two autonomous brigades, an autonomous regiment and several autonomous artillery detachments. With its manpower, it was the largest single contributor to Army Group A's overall manpower of 400,556. Unknown to the Wehrmacht, the Soviet command planned to saturate the entire defensive zone with artillery bombardment. The Red Army began their Vistula–Oder Offensive on January 17, quickly encircling the LVI Panzer Corps and destroying half of all armoured forces concentrated with the 4th Panzer Army. The commander of the LVI Corps, General Johannes Block, was killed in action on 26 January. The remnants of the army retreated along the entire front before re-grouping on the western bank of the Oder River in February 1945. The Red Army halted its offensive in February 1945. The 3rd Panzer Army was tasked to halt the Soviets in the north, while the 9th Army was guarding against the Soviets in the centre.
== Prognosis == G6PD-deficient individuals do not appear to acquire any illnesses more frequently than other people, and may have less risk than other people for acquiring ischemic heart disease and cerebrovascular disease. However, a recent study revealed that G6PD deficiency increases cardiovascular risk by up to 70%. The risk conferred by G6PD deficiency is moderate compared with the impact of primary cardiovascular risk factors. Besides, a published review hypothesized that G6PD deficiency could reduce the antiplatelet efficacy of clopidogrel (clopidogrel resistance).
=== Legal status === Tiratricol was once an approved medication in Brazil, but its marketing authorization was suspended in 2003. Tiratricol is available in France for therapy of thyroid hormone resistance and adjuvant therapy of thyroid cancer. In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Emcitate, intended for the treatment of MCT8 deficiency (Allan-Herndon-Dudley syndrome). The applicant for this medicinal product is Rare Thyroid Therapeutics International AB. Emcitate is a hybrid medicine of Téatrois, which has been authorized in France. Emcitate contains the same active substance as Téatrois but has a different indication. Tiratricol was authorized for medical use in the European Union in February 2025. Tiratricol was approved for medical use in the United States in September 2026. The US Food and Drug Administration (FDA) granted the application for tiratricol orphan drug, rare pediatric disease, fast track, breakthrough therapy, and priority review designations. The FDA granted the approval of Emcitate to Egetis Therapeutics US.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.